H epatitis C virus (HCV)-related liver failure is the leading indication for orthotopic liver transplantation (OLT) worldwide. After liver transplantation, recurrence of HCV infection occurs in virtually all patients. The majority show HCV-induced allograft hepatitis after follow-up of at least 5 years (1) . The natural history of the disease is characterized by progression to cirrhosis in 6% to 23% of patients at a median of 3 to 4 years after transplantation; the estimated cumulative probability of developing HCV-related graft cirrhosis at 5 years is 30% (1) (2) (3) (4) . The development of cirrhosis is associated with reduced graft and patient survival (2) , and once cirrhosis is established, the 1-year actuarial risk for decompensation is 42% (5) .
HCV-related disease progression is particularly aggressive in the posttransplantation setting. Fibrosis progresses significantly faster than in immunocompetent patients (6) , suggesting that the time to the development of cirrhosis is shorter-approximately 9 to 12 years (6) . The rate of progression is affected by a range of virus-, host-, and environmentrelated variables (7) , namely: donor and recipient age, sex, and histocompatibility; year of transplantation; pretransplantation HCV RNA levels; viral genotype and quasispecies; use of immunosuppressive agents; and histological findings on the first liver biopsy.
Platelet-derived growth factor (PDGF), a cationic glycoprotein of 24 kDa, is reportedly involved in the pathogenesis of liver fibrosis (8 -11) . PDGF is released by endothelial cells, macrophages, fibroblasts, and vascular smooth muscle cells as a homo-or heterodimer composed of PDGF-A or PDGF-B chains. It exists as an AA, BB, or AB isoform, covalently linked by disulfide bonds (12) . It has been implicated in the fibroproliferative response in various chronic inflammatory disorders (13) . The human PDGF-B gene has been localized to chromosome 22 (q12.3-q13.1) and spans 12 kb of V-cis-related sequences interrupted by four intervening sequences (14) . Novel single nucleotide polymorphisms were noted in the promoters, 5=-UTRs and introns of PDGF-B. Substitutions observed were G¡A at position ϩ286 (5=-UTR, accession number AF169594) and A¡C at position ϩ1135 (first intron, accession number AF169595 (newly discovered by Ian Hutchinson and Vera Pravica, co-authors). There is no linkage disequilibrium between the two polymorphisms. In the liver, PDGF is released by inflammatory cells and promotes the proliferation of hepatic stellate cells (HSCs), the main source of extracellular matrix proteins (15) . During hepatic fibrogenesis, PDGF is overexpressed (16) , and HSCs undergo a process of activation, developing a myofibroblast-like phenotype (17) associated with increased proliferation and collagen synthesis (18) . PDGF-B is the best characterized chemotactic factor for HSCs (19 -21) , and is recognized as their most potent mitogen.
The aim of the present study was to evaluate the possible association of molecular variants in the gene encoding PDGF-B with the risk of developing recurrent HCV infection after liver transplantation and with its severity.
PATIENTS AND METHODS

Patients
The initial sample included all 46 patients who underwent OLT for chronic HCV infection at Rabin Medical Center between 1992 and 2002. Six were later excluded because of concomitant alcoholic liver disease (nϭ2), a history of hepatitis B (nϭ2), or missing data (nϭ2). All participants had more than 1 year of follow-up (mean, 49.3Ϯ28.4 months). The diagnosis of recurrent HCV infection was based on the presence of viremia by quantitative polymerase chain reaction (PCR) assay, increased serum transaminase levels, and histologic findings at diagnosis of lobular hepatitis in association with hepatocyte necrosis and midzonal macrovesicular steatosis. The immunosuppressive regimen included cyclosporine, azathioprine, or mycophenolate mofetil (CellCept), in addition to corticosteroids in 17 patients and tacrolimus and corticosteroids in 23 patients. Episodes of acute, histologically proven cellular rejection were treated with three consecutive boluses of intravenous Solu-Medrol, 1.0 g/d, and steroid-resistant episodes were treated with OKT3.
Patient files were reviewed for demographic characteristics, pretransplant HCV RNA load and genotype, immunosuppressive regimen, rejection episodes, interval to recurrence, and clinical progression at follow-up based on levels of serum bilirubin, and alanine aminotransferase (ALT), presence of hepatic decompensation, retransplantation, and death due to recurrent HCV infection.
Severe recurrence was defined as stage 3-4 fibrosis, or the presence of recurrent fibrosing cholestasis or graft failure (22) .
The control group included 47 healthy (HCV Ab-negative, HCV RNA-negative) volunteers (25 male, 22 female; mean age, 50.3Ϯ9.8 years) matched for sex and age (HCV Ab negative, HCV RNA negative) to the study group.
Genetic Polymorphism Assessment
The genetic profile of PDGF-B was analyzed in all patients.
DNA Extraction
Genomic DNA was isolated by proteinase K digestion of fresh peripheral blood mononuclear cells, followed by phenol extraction and ethanol precipitation. DNA samples were quantified and subjected to specific PCR reactions as described.
PDGF-B Gene Polymorphism
DNA was amplified by amplification refractory mutation system-polymerase chain reaction (ARMS-based PCR) (23) in a 10:1 reaction containing 200 M deoxyribonucleoside (dNTPs); 1.5 mM magnesium chloride; 8.5% sucrose (w/v); 0.25 units Taq polymerase; 5 M specific control primers and 1 M internal control primers. PDGF-B ϩ286 primers were designed (by Pravica V & Hutchinson I) to detect an A to G polymorphism: 5=-AAGGCCGGAACAGCTGAAA-3= and GGTCCGTCTGCCCGCCC/T; PCR product size was 323 bp. PDGF-B ϩ1135 primers were designed to detect an A to C polymorphism: 5=-TGTTCTCGGGTTCCCAAAGG-3= and ATTCATTACCTTCGCCCCCC/A; PCR product size was 263 bp. The internal control primers amplified the human growth hormone gene: sense primer 5=-GCCTTCCCAAC-CATTCCCTTA-3= and antisense primer 5=-TCACGGATT-TCTGTTGTGTTTC-3Ј; PCR product size was 429 bp. PCR included 1 cycle of 95°Cϫ1 min; 10 cycles of 95°Cϫ15 seconds, 69°Cϫ50 seconds, 72°Cϫ40 seconds; and 20 cycles of 95°Cϫ20 seconds, 59°Cϫ50 seconds, 72°Cϫ50 seconds.
Method validation was performed using alternative techniques: restriction fragment length polymorphism.
Histological Assessment
One pathologist (O.P.) blindly reviewed all hepatic specimens of the patients for overall necroinflammatory activity (grade 0 to 12) and fibrosis (stage 0 to 4) according to Knodell's score. Intercurrent disease processes, such as acute cellular rejection, cytomegalovirus infection, biliary obstruction, and ischemia were ruled out by serologic, immunohistochemical, radiological and endoscopic studies.
PDGF-B Immunohistochemistry Staining and Scoring
Immunohistology was performed on deparaffinized liver biopsy sections.
Briefly, sections (4 l) of formalin-fixed, paraffin-embedded tissues were immunostained with mouse antihuman PDGF-B (U 376-UC, BioGenex, San Ramon, CA) diluted 1:100. Antigen retrieval was performed before application of the primary antibody. The tissue sections were placed in a bath with citrate buffer pHϭ6.0 and microwaved in a pressure cooker on high power (900 -1000 W) for 13 min until the pressure cooker was fully pressurized. Thereafter, the microwave level was reduced to 40% for another 5 min. Endogenous peroxidase reactions were blocked using Dako's blocking kit (Dako Co., Carpinterie, CA). Sections were then incubated with the primary antibody for 45 min followed with the Dako LSAB ϩ kit peroxidase, which consists of labeled streptavidin biotin reagents. Reactive sites were revealed by incubation with DAB (3.3-diaminobenzidine) (Dako). Sections were counterstained with hematoxylin. Positive controls were sections of squamous carcinoma and negative controls were the liver biopsies run concurrently without the primary antibody.
The intrahepatic PDGF-B expression was evaluated semiquantitatively according to the number of cells that stained positively (24) .
Virological Assays
HCV RNA was tested by nested reverse-transcription polymerase chain reaction assay (RT-PCR) (Cobas Amplicor HCV Monitor Test, Roche Diagnostic Systems, Branchburg, NJ). Analytical sensitivity of the assay was 600 IU/ml. HCV genotypes were determined by a line-probe hybridization assay (INNO-LiPa Innogenetics, Ghent, Belgium) directed to the 5= untranslated regions of the different HCV genotypes.
Statistical Analysis
Pearson and Spearman correlation coefficients and the significance for it (p) were calculated between the variables.
Chi-squared test or Fisher exact test were used, as appropriate, to analyze statistically significant relationships between categorical variables (i.e., study vs. control group, recurrence, mutations ϩ286 and ϩ1135), and chi-squared test for equal proportions was used to analyze the distribution of each type of mutation between the study and control groups. Student t test was used to analyze statistically significant differences in mean continuous parameters between the groups. To analyze statistically significant differences in mean continuous parameters between more than two groups of categorical variables, analysis of variance was used with Duncan multiple comparison option. Due to the small sample size in some subgroups, a non-parametric Kruskal-Wallis test was also done. Multivariate stepwise logistic regression models were fitted to the data in order to predict mortality, disease recurrence or disease severity. A p value less than or equal to 0.05 was considered statistically significant.
RESULTS
The baseline characteristics of the patients in this study are presented in Table 1 : mean age was 52.7Ϯ9.6 years; 52.5% were male. HCV genotypes were available for 30 patients: 26 (86.6%) were genotype 1, 3 were genotype 2a and one was genotype 3a. Mean pretransplant HCV RNA load was 414,954.8Ϯ880,991.4 IU/ml. The immunosuppressive regimen was based on cyclosporine in 35% of the patients and on tacrolimus in 65%. The rejection rate was 45% (in 18 patients). Of these, 12 patients developed mild rejection, five moderate, and only one patient severe (treated with OKT3).
Recurrent HCV infection developed in 34 patients (85%) after a median interval of 10.5 months (range 1.5-60.0 months); in 8 patients, the recurrent infection appeared early (Ͻ12 months) and was severe. Mean serum ALT level at recurrence was 139.7Ϯ121.0 U/L, and mean serum bilirubin, 1.8Ϯ2.0 mg/dl; mean necroinflammatory score was 5.3Ϯ2.4, and mean fibrosis score, 1.7Ϯ1.1. Six of the 34 patients (17.6%) showed histologically proven cirrhosis during the follow-up period. The mean duration of follow-up was 49.8Ϯ28.4 months. The remaining six patients did not have histological recurrence of HCV. In all of them, liver biopsy was done during follow-up because of an increase in serum ALT level, which was found to be due to other causes and ultimately resolved.
Phenotypic Expression
The genotype and allele frequencies were determined in patients and controls (Table 2) .
A statistically significant difference was observed in the distribution of the PDGF-B gene polymorphism at position ϩ1135 between the patients who underwent liver transplantation for HCV and the control group (Pϭ0.05). However, no such statistically significant difference was observed at position ϩ286. Table 3 summarizes the phenotypic expression deduced from the gene polymorphism in PDGF-B in the patients with and without HCV infection after liver transplantation and in the patients with severe and non-severe recurrent disease. The allelic polymorphism of PDGF-B at position ϩ1135 examined the presence of an A or C nucleo- (Fig. 1) . A highly statistically significant difference was also observed among the patients with recurrence, by severity of disease (Pϭ0.05). All patients with severe recurrence had the A/A genotype. Of the patients with non-severe recurrence, 53.85% exhibited the A/A genotype, 42.31% the A/C genotype, and 3.84% the C/C genotype (Fig. 1) .
The allelic polymorphism of PDGF-B at position ϩ286 examined the presence of an A or G nucleotide in this position, which translated directly into three phenotypic expressions. No statistically significant difference was observed between the patients who developed a recurrent HCV infection and those who did not (Table 3 ). Within the group of patients with a recurrence, there was no statistical difference between those with severe and non-severe recurrent disease (Table 3) .
Intrahepatic PDGF-B Immunohistochemistry
There was a statistically significant difference between the PDGF-B gene polymorphism at position ϩ1135 and the intrahepatic immunohistochemistry for PDGF-B (Pϭ0.027). PDGF-B immunoreactivity was found in mesenchymal cells of portal areas and fibrous septa localized diffusely in the cytoplasm compartment. A highly statistically significant correlation was found between the intrahepatic immunohistochemistry for PDGF-B and the fibrosis score (PϽ0.0001). The number of positive cells increased with progression of fibrosis (Figs. 2 and 3) (Table 4) . No statistically significant correlation was found between PDGF-B immunohistochemistry and the necroinflammatory score. A statistically significant correlation was found between PDGF-B immunohistochemistry and the serum bilirubin level (Pϭ0.003), serum ALT (Pϭ0.0002), severity of recurrence (Pϭ0.0008), death due to HCV (Pϭ0.0004).
Relationship between the PDGF-B Gene Polymorphism and Clinical Parameters
On univariate analysis, highly statistically significant correlation was noted between the PDGF-B gene polymor- phism at position ϩ1135 and recurrent HCV infection (Pϭ0.001), serum ALT level (Pϭ0.007), and serum bilirubin level (Pϭ0.04) at recurrence, necroinflammatory score (Pϭ0.03), fibrosis score (Pϭ0.001), cirrhosis (Pϭ0.003), severe recurrence (Pϭ0.022), and death due to recurrent HCV infection (8 patients) (Pϭ0.06) ( Table 5) . Factors found to have no association were immunosuppressive regimen, rejection episodes, viral load, and viral genotype before transplantation, time to recurrence and retransplantation. Although multivariate analysis was performed, no statistical predictive factors were entered into the model due to sample size restrictions (small number of deaths or recurrence events).
No statistically significant correlation was noted between the PDGF-B gene polymorphism at position ϩ286 and the studied clinical parameters (Table 5) , except for the necroinflammatory score (Pϭ0.04).
DISCUSSION
Variables associated with the rapid disease progression of HCV reinfection after transplantation are under intensive investigation (7) . To the best of our knowledge, this is the first study to examine the role of molecular variants of the gene encoding PDGF-B in this process.
We focused on two PDGF-B gene polymorphisms, at positions ϩ1135 (A to C) and ϩ286 (A to G). A statistically significant difference was noted in the distribution of the PDGF-B polymorphism at position ϩ1135 between the study and control groups (Pϭ0.05). No such relationship was found for position ϩ286. Further analysis yielded significant relationships of the polymorphism at position ϩ1135 with both risk of recurrence and its severity. Specifically, the A/A genotype occurred at a significantly higher rate in patients with recurrence than in those without (64.7% vs. 16.67%, Pϭ0.0001), and in patients with severe recurrence than in those with non-severe recurrence (100% vs. 53.85%, Pϭ0.05). In addition, the polymorphism at position ϩ1135 was associated with higher clinical parameters of disease at recurrence (serum ALT, bilirubin, fibrosis score, cirrhosis, and severity of infection). Due to the small number of events (death or recurrence), the model could not be fitted into a multivariate context. By contrast, the PDGF gene polymorphism at position ϩ286 did not correlate with recurrent HCV infection (pϭNS).
These findings might help to shed light on the mechanisms underlying the accelerated course of HCV infection in liver transplant recipients compared to immune-competent individuals (6) both before and after the development of cirrhosis (5). The posttransplantation period is known to be characterized by a faster rate of fibrogenesis until graft cirrhosis develops and a greater risk of subsequent decompensation than before transplantation (3, 6, (25) (26) (27) . Nevertheless although most patients develop recurrent HCV within 5 years, some maintain minimal to moderate liver damage whereas others advance rapidly to end-stage disease and graft failure (1-3, 6, 28) . One of the key mediators of progressive liver disease are HSCs (15, 18) , they are considered to be the main source of extracellular matrix protein in the liver (19 -21) . The present study was prompted by evidence indicating that the PDGF-B is one of the most potent mitogenic factor for HSCs (19 -21) . PDGF is overexpressed during active hepatic fibrogenesis and may be involved in the transformation of HSCs to myofibroblast-like cells in vivo (16) . These findings were supported by the study of Pinzani et al. (29) might prevent aggressive liver fibrosis and improve prognosis in patients with recurrent HCV infection after liver transplantation. Our data emphasize the potential importance of PDGF-B gene polymorphism in recurrent severe HCV infection and the role of PDGF-B in the development and progression of hepatic fibrosis. Further analysis in a larger cohort of patients is needed to confirm our results. These findings, if confirmed, may ultimately help clinicians therapy in selected patients at risk to design preemptive preventive
